pubmed.ncbi.nlm.nih.gov

Advances in Alzheimer's disease's pharmacological treatment - PubMed

  • ️Sun Jan 01 2023

Review

Advances in Alzheimer's disease's pharmacological treatment

Carlos Elias Conti Filho et al. Front Pharmacol. 2023.

Abstract

Alzheimer's disease (AD) is the most common type of dementia in the elderly. Several hypotheses emerged from AD pathophysiological mechanisms. However, no neuronal protective or regenerative drug is available nowadays. Researchers still work in drug development and are finding new molecular targets to treat AD. Therefore, this study aimed to summarize main advances in AD pharmacological therapy. Clinical trials registered in the National Library of Medicine database were selected and analyzed accordingly to molecular targets, therapeutic effects, and safety profile. The most common outcome was the lack of efficacy. Only seven trials concluded that tested drugs were safe and induced any kind of therapeutic improvement. Three works showed therapeutic effects followed by toxicity. In addition to aducanumab recent FDA approval, antibodies against amyloid-β (Aβ) showed no noteworthy results. 5-HT6 antagonists, tau inhibitors and nicotinic agonists' data were discouraging. However, anti-Aβ vaccine, BACE inhibitor and anti-neuroinflammation drugs showed promising results.

Keywords: Alzheimer’s disease; drug development; molecular target; new drugs; pharmacological treatment.

Copyright © 2023 Conti Filho, Loss, Marcolongo-Pereira, Rossoni Junior, Barcelos, Chiarelli-Neto, Silva, Passamani Ambrosio, Castro, Teixeira and Mezzomo.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1

Main potential targets for drug design in AD and relation of its pathways. (A) AD’s targets used to develop new drugs in clinical trials evaluated in this work. (B) All mechanisms related to AD pathogenesis and progression are connected and were explored in these clinical trials, such as Aβ and tau aggregation; BACE-1, γ-secretase, or glutaminyl cyclase activity; neuroinflammation; excitotoxicity; 5-HT7R or 5-HT6R hyperstimulation and cholinergic impairment.

Similar articles

Cited by

References

    1. Abdullah L., Crawford F., Tsolaki M., Börjesson-Hanson A., Olde Rikkert M., Pasquier F., et al. (2020). The influence of baseline Alzheimer's disease severity on cognitive decline and CSF biomarkers in the NILVAD trial. Front. Neurol. 11, 149. 10.3389/fneur.2020.00149 - DOI - PMC - PubMed
    1. Alzheimer A., Stelzmann R. A., Schnitzlein H. N., Murtagh F. R. (1995). An English translation of Alzheimer's 1907 paper Uber eine eigenartige Erkankung der Hirnrinde. Clin. Anat. 6, 429–431. 10.1002/ca.980080612 - DOI - PubMed
    1. Alzheimer A. (1906). Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurol. Cent. 23, 1129–1136.
    1. Andrews M., Tousi B., Sabbagh M. N. (2018). 5HT6 antagonists in the treatment of Alzheimer’s dementia: Current progress. Neurol. Ther. 7, 51–58. 10.1007/s40120-018-0095-y - DOI - PMC - PubMed
    1. Arai H., Umemura K., Ichimiya Y., Iseki E., Eto K., Miyakawa K., et al. (2016). Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease. Geriatr. Gerontol. Int. 5, 644–650. 10.1111/ggi.12516 - DOI - PubMed

Publication types

Grants and funding

This work was supported by Fundação de Amparo à Pesquisa e Inovação do Espírito Santo (FAPES) grant number 931/2022 P: 2022-2N1DV.

LinkOut - more resources